https://www.chiesi.com/en.html2026-10-06T15:59:02.891Zhttps://www.chiesi.com/en/about-us.html2026-10-06T10:08:25.216Zhttps://www.chiesi.com/en/about-us/our-history.html2026-10-01T12:25:14.91Zhttps://www.chiesi.com/en/about-us/who-we-are-today.html2026-10-06T10:52:53.778Zhttps://www.chiesi.com/en/about-us/ethics-and-transparency.html2026-10-06T14:22:04.567Zhttps://www.chiesi.com/en/about-us/ethics-and-transparency/clinical-trial-transparency-and-data-sharing.html2026-09-21T15:18:08.194Zhttps://www.chiesi.com/en/about-us/ethics-and-transparency/efpia-countries-report.html2026-10-02T10:22:33.055Zhttps://www.chiesi.com/en/about-us/ethics-and-transparency/efpia-countries-report/switzerland.html2026-10-02T10:26:24.751Zhttps://www.chiesi.com/en/about-us/our-governance.html2026-10-06T14:03:48.462Zhttps://www.chiesi.com/en/sustainability.html2026-10-06T10:13:38.433Zhttps://www.chiesi.com/en/medical-information.html2026-10-02T14:41:42.408Zhttps://www.chiesi.com/en/contacts.html2026-10-06T11:23:21.618Zhttps://www.chiesi.com/en/contacts/chiesi-in-the-world.html2026-09-28T08:35:48.378Zhttps://www.chiesi.com/en/speakup-and-beheard.html2026-09-23T12:32:57.361Zhttps://www.chiesi.com/en/our-approach.html2026-10-06T10:06:43.275Zhttps://www.chiesi.com/en/join-us.html2026-09-29T14:19:46.152Zhttps://www.chiesi.com/en/our-solutions.html2026-10-06T09:26:46.087Zhttps://www.chiesi.com/en/our-solutions/respiratory.html2026-10-06T09:49:13.706Zhttps://www.chiesi.com/en/our-solutions/rare-diseases.html2026-10-06T09:34:06.952Zhttps://www.chiesi.com/en/our-solutions/our-pipeline.html2026-09-18T12:46:42.772Zhttps://www.chiesi.com/en/our-solutions/specialty-care.html2026-10-06T10:04:04.796Zhttps://www.chiesi.com/en/media-hub.html2026-09-18T12:46:44.151Zhttps://www.chiesi.com/en/media-hub/stories/health-equity-in-action.html2026-10-06T10:52:33.616Zhttps://www.chiesi.com/en/media-hub/stories/inside-our-biotech-centre-of-excellence.html2026-09-29T07:45:02.941Zhttps://www.chiesi.com/en/media-hub/stories/looking-beyond-the-boundaries-of-chiesi.html2026-09-29T11:10:18.438Zhttps://www.chiesi.com/en/media-hub/stories/our-path-to-net-zero.html2026-09-28T10:36:50.726Zhttps://www.chiesi.com/en/media-hub/stories/the-digital-lung-twin.html2026-09-30T08:53:20.811Zhttps://www.chiesi.com/en/media-hub/stories/every-newborn-counts-every-breath-matters.html2026-09-25T13:20:09.314Zhttps://www.chiesi.com/en/media-hub/stories/carbon-minimal-inhaler-program.html2026-10-06T12:40:51.867Zhttps://www.chiesi.com/en/media-hub/press-release/europe-approves-holoclar-the-first-stem-cell-based-medicinal-product.html2026-09-18T12:46:48.752Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-farmaceutici-group-confirms-growth-and-investment-trend-for-2014.html2026-09-18T12:46:48.795Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-to-acquire-3-hospital-products.html2026-09-18T12:46:48.836Zhttps://www.chiesi.com/en/media-hub/press-release/an-extrafine-ics-laba-combination-decreases-copd-exacerbations-more-than.html2026-09-18T12:46:48.879Zhttps://www.chiesi.com/en/media-hub/press-release/patients-with-copd-benefit-from-the-chiesi-extrafine-fixed-triple-combination-icslabalama-highly-effective-and-easy-to-use.html2026-09-18T12:46:48.922Zhttps://www.chiesi.com/en/media-hub/press-release/the-lancet-publishes-the-results-of-chiesi-farmaceutici-trilogy-study.html2026-09-18T12:46:48.966Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-farmaceutici-is-the-first-company-to-submit-a-marketing-authorisation-application-to-the-european-medicine-agency-for-a-triple-combination-for-the-treatment-of-copd.html2026-09-18T12:46:49.011Zhttps://www.chiesi.com/en/media-hub/press-release/the-italian-prime-minister-matteo-renzi-has-visited-chiesi-farmaceutici-research-center-in-parma.html2026-09-18T12:46:49.052Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-enhances-asthma-portfolio-with-acquisition-of-atopix-therapeutics.html2026-09-18T12:46:49.1Zhttps://www.chiesi.com/en/media-hub/press-release/gold-2017-report-chiesi-farmaceutici-highlights-relevant-gaps.html2026-09-18T12:46:49.143Zhttps://www.chiesi.com/en/media-hub/press-release/for-the-second-time-chiesis-extrafine-fixed-dose-icslabalama-triple-therapy-earns-a-place-in-the-pages-of-the-lancet-with-the-publication-of-chiesis-trinity-study.html2026-09-18T12:46:49.186Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-reports-an-increased-turnover-in-2016-and-consolidates-its-global-presence.html2026-09-18T12:46:49.377Zhttps://www.chiesi.com/en/media-hub/press-release/glybera-alipogene-tiparvovec-in-europe.html2026-09-18T12:46:49.425Zhttps://www.chiesi.com/en/media-hub/press-release/trimbow-is-the-first-triple-combination-in-a-single-inhaler-for-the-treatment-of-copd-to-receive-positive-opinion-from-the-chmp-in-europe.html2026-09-18T12:46:49.473Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-receives-the-european-marketing-authorisation-for-trimbow-inhaled-corticosteroid-long-acting-i2-agonist-long-acting-muscarinic-antagonist.html2026-09-18T12:46:49.521Zhttps://www.chiesi.com/en/media-hub/press-release/tribute-study-shows-superiority-of-chiesis-trimbow-beclometasone-dipropionate-bdp-formoterol-fumarate-ff-and-glycopyrronium-gb-over-ultibro-indacaterolglycopyrronium-in-reducing-copd-exacerbations1.html2026-09-18T12:46:49.569Zhttps://www.chiesi.com/en/media-hub/press-release/new-study-published-in-the-lancet-shows-trimbow-beclometasoneformoterolglycopyrronium-superiority-over-ultibro-breezhaler-indacaterolglycopyrronium-in-reducing-copd-exacerbations1.html2026-09-18T12:46:49.614Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-confirmed-top-employer-2018-in-italy-and-europe.html2026-09-18T12:46:49.657Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-receives-positive-opinion-from-chmp-for-lamzede-velmanase-alfa-the-first-therapy-for-alpha-mannosidosis.html2026-09-18T12:46:49.702Zhttps://www.chiesi.com/en/media-hub/press-release/the-chiesi-group-is-one-of-the-8-italian-companies-invited-by-macron-to-the-french-international-summit-in-versailles.html2026-09-18T12:46:49.746Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-is-the-first-italian-pharmaceutical-company-for-investments-in-research-and-development.html2026-09-18T12:46:49.79Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-hosts-groundbreaking-ceremony-for-the-groups-future-headquarters.html2026-09-18T12:46:49.833Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-receives-the-european-marketing-authorisation-for-lamzedevelmanase-alfa.html2026-09-18T12:46:49.878Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-and-holostem-announce-fda-orphan-drug-designation-for-gplscd01-for-treatment-of-limbal-stem-cell-deficiency-lscd.html2026-09-18T12:46:49.927Zhttps://www.chiesi.com/en/media-hub/press-release/protalix-biotherapeutics-expands-partnership-with-chiesi-farmaceutici-to-include-exclusive-us-rights-for-the-development-and-commercialization-of-prx-102-pegunigalsidase-alfa.html2026-09-18T12:46:49.974Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-acquires-nhco-nutrition-sas-and-strengthens-its-otc-portfolio-in-france.html2026-09-18T12:46:50.017Zhttps://www.chiesi.com/en/media-hub/press-release/copd-a-disease-still-underestimated-by-europeans-absence-of-perceived-risk-according-to-eurisko-survey.html2026-09-18T12:46:50.061Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-farmaceutici-changes-statute-to-become-lbenefit-corporationr.html2026-09-18T12:46:50.109Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-receives-the-eurordis-black-pearl-award-for-innovation-in-the-field-of-rare-disease.html2026-09-18T12:46:50.151Zhttps://www.chiesi.com/en/media-hub/press-release/paolo-chiesi-appointed-honorary-doctor-at-karolinska-institutet.html2026-09-18T12:46:50.193Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-is-the-largest-pharmaceutical-group-in-the-world-to-be-awarded-b-corp-certification.html2026-09-18T12:46:50.236Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-confirms-positive-trend-to-date-for-2019.html2026-09-18T12:46:50.278Zhttps://www.chiesi.com/en/media-hub/press-release/we-act-day-2019-chiesi-sets-itself-the-challenge-of-becoming-carbon-neutral-by-2035.html2026-09-18T12:46:50.319Zhttps://www.chiesi.com/en/media-hub/press-release/single-inhaler-extrafine-triple-therapy-of-inhaled-corticosteroid-plus-long-acting-2-agonist.html2026-09-18T12:46:50.363Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-receives-diversity-leaders-award-2020.html2026-09-18T12:46:50.404Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-outlines-350-million-investment-and-announces-first-carbon-minimal-pressurised-metered-dose-inhaler-pmdi-for-asthma-and-copd.html2026-09-18T12:46:50.446Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-joins-the-cooperative-compliance-programme-run-by-the-italian-revenue-agency.html2026-09-18T12:46:50.488Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-sponsors-parma-capital-of-culture-2020.html2026-09-18T12:46:50.531Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-confirmed-top-employer-2020-in-italy-and-europe.html2026-09-18T12:46:50.577Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-increases-support-measures-and-announces-new-funds-for-employees-patients-and-healthcare-providers-in-response-to-covid-19-pandemic.html2026-09-18T12:46:50.621Zhttps://www.chiesi.com/en/media-hub/press-release/bioasis-and-chiesi-group-announce-rare-diseases-strategic-alliance.html2026-09-18T12:46:50.663Zhttps://www.chiesi.com/en/media-hub/press-release/thomas-eichholtz-appointed-new-head-of-global-research-and-development-at-the-chiesi-group.html2026-09-18T12:46:50.706Zhttps://www.chiesi.com/en/media-hub/press-release/bioasis-and-chiesi-group-to-host-webcast-on-july-16-2020.html2026-09-18T12:46:50.748Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-publishes-its-annual-report-group-generates-almost-2-billion-and-obtains-b-corp-certification-in-2019.html2026-09-18T12:46:50.79Zhttps://www.chiesi.com/en/media-hub/press-release/moderna-and-chiesi-group-establish-collaboration-to-discover-and-develop-mrna-therapeutics-for-pulmonary-arterial-hypertension-pah.html2026-09-18T12:46:50.835Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-farmaceutici-president-appointed-knight-of-the-legion-drhonneur.html2026-09-18T12:46:50.877Zhttps://www.chiesi.com/en/media-hub/press-release/we-act-day-2020-the-third-edition-of-chiesis-event-for-a-sustainable-future.html2026-09-18T12:46:50.92Zhttps://www.chiesi.com/en/media-hub/press-release/maria-paola-chiesi-received-by-the-president-of-the-italian-republic-for-the-2020-bellisario-award-ceremony.html2026-09-18T12:46:50.964Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-launches-the-art-of-caring-a-journey-in-search-of-the-link-between-parma-officinal-treatments-and-pharmaceutics.html2026-09-18T12:46:51.008Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-receives-diversity-leaders-award-2021.html2026-09-18T12:46:51.05Zhttps://www.chiesi.com/en/media-hub/press-release/kaia-health-and-chiesi-group-announce-strategic-partnership-to-commercialise-kaia-copd-pulmonary-rehabilitation-app-in-european-markets.html2026-09-18T12:46:51.094Zhttps://www.chiesi.com/en/media-hub/press-release/infermieri-a-viso-aperto-a-photographic-project-bringing-to-light-the-faces-and-stories-of-those-who-help-patients-every-day.html2026-09-18T12:46:51.137Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-headquarters-an-innovative-sustainable-and-people-friendly-home-the-first-building-in-its-category-to-be-certified-leed-platinum-in-italy-a-people-oriented-project.html2026-09-18T12:46:51.184Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-receives-the-european-marketing-authorisation-for-trimbowr-28beclometasone-dipropionate-2c-formoterol-fumarate-2c-glycopyrronium-29-an-extrafine-formulation-fixed-triple-combination-therapy-for-the-treatment-of-asthma.html2026-09-18T12:46:51.231Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-global-rare-diseases-recognizes-rare-disease-day-highlighting-importance-of-staying-connected-for-information-and-support.html2026-09-18T12:46:51.275Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-performance-is-up-in-2020.html2026-09-18T12:46:51.318Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-continues-cultural-transformation-with-new-visual-identity-that-mirrors-patientsr-language-and-experiences.html2026-09-18T12:46:51.362Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-receives-eu-authorisation-for-nexthaler-in-copd.html2026-09-26T21:15:01.834Zhttps://www.chiesi.com/en/media-hub/press-release/new-organisational-order-for-the-chiesi-foundation.html2026-09-18T12:46:51.451Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-calls-for-actionoverwords-in-the-fight-against-climate-change.html2026-09-18T12:46:51.494Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-accelerates-path-toward-full-sustainability-despite-covid-19-pandemic.html2026-09-18T12:46:51.538Zhttps://www.chiesi.com/en/media-hub/press-release/ers-congress-2021-n-important-updates-on-asthma-and-copd-treatments-presented-at-the-symposium-organised-by-chiesi-lunlock-every-breath-finding-the-right-key-to-improve-respiratory-therapyr.html2026-09-18T12:46:51.581Zhttps://www.chiesi.com/en/media-hub/press-release/climate-change-major-threat-to-respiratory-health-in-europe.html2026-09-18T12:46:51.626Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-receives-positive-esg-rating-from-independent-rating-agency-cerved.html2026-09-18T12:46:51.669Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-research-centre-10-yearsr-scientific-innovation-serving-the-community.html2026-09-18T12:46:51.714Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-and-ucb-enter-global-license-agreement-for-zampilimab-a-novel-monoclonal-antibody-for-fibrotic-lung-diseases.html2026-09-18T12:46:51.756Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-headquarters-takes-centre-stage-in-the-monograph-lspazio-lavoro-architetturar-28space-work-architecture-29-electaarchitettura-editions.html2026-09-18T12:46:51.808Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-focuses-on-biological-drugs-an-investment-of-85-million-euros-for-an-international-centre-of-excellence-in-parma.html2026-09-18T12:46:51.852Zhttps://www.chiesi.com/en/media-hub/press-release/a-new-clinical-framework-redefines-the-diagnosis-of-copd-exacerbations.html2026-09-18T12:46:51.896Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-france-receives-choose-frances-contribution-au-plan-de-relance-contribution-to-stimulus-plan-special-award-from-the-minister-for-territorial-cohesion-and-relations-with-local-authorities.html2026-09-18T12:46:51.942Zhttps://www.chiesi.com/en/media-hub/press-release/solidarity-actions-to-support-the-people-affected-by-the-war.html2026-09-18T12:46:51.983Zhttps://www.chiesi.com/en/media-hub/press-release/koura-opens-worldrs-first-hfa-152a-medical-propellant-production-facility.html2026-09-18T12:46:52.026Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-continues-to-grow.html2026-09-18T12:46:52.068Zhttps://www.chiesi.com/en/media-hub/press-release/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-topline-results-from-the-24-month-phase-iii-balance-clinical-trial-of-prx-102-for-the-treatment-of-fabry-disease.html2026-09-18T12:46:52.115Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-acquires-pioneering-therapeutic-monoclonal-antibodies-portfolio-against-emap-ii-as-potential-treatment-for-pah.html2026-09-18T12:46:52.158Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-tracks-actions-taken-for-a-healthier-2c-more-sustainable-future.html2026-09-18T12:46:52.2Zhttps://www.chiesi.com/en/media-hub/press-release/first-carbon-minimal-pmdi-is-on-track-with-the-goal-to-benefit-patients-and-planet.html2026-09-18T12:46:52.244Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-announces-the-departure-of-ugo-di-francesco-as-ceo-of-the-group.html2026-09-18T12:46:52.285Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-brings-together-experts-to-discuss-care-for-respiratory-patients-and-presents-a-new-treatment-option-for-copd-at-ers-congress.html2026-09-18T12:46:52.33Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-is-recertified-as-a-b-corp-and-sets-new-tougher-objectives-for-action-by-2025.html2026-09-18T12:46:52.372Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-and-aptar-partner-to-bring-to-market-disease-management-platform-for-patients-with-asthma-and-copd.html2026-09-18T12:46:52.415Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-groups-new-biotech-center-of-excellence-brings-the-future-of-medicine-to-parma.html2026-09-18T12:46:52.463Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-endorses-the-manifesto-against-gender-based-violence.html2026-09-18T12:46:52.508Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-communicates-that-it-is-not-involved-in-the-events-concerning-the-holostem-company.html2026-09-18T12:46:52.553Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-farmaceutici-s-p-a-to-acquire-amryt-pharma-plc.html2026-09-18T12:46:52.597Zhttps://www.chiesi.com/en/media-hub/press-release/important-recognitions-for-chiesi-group-from-the-carbon-disclosure-project-cdp-and-cerved-rating-agency.html2026-09-18T12:46:52.642Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-appoints-giuseppe-accogli-as-new-group-ceo.html2026-09-18T12:46:52.685Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-global-rare-diseases-announces-fda-approval-of-lamzede-velmanase-alfa-tycv-for-alpha-mannosidosis.html2026-09-18T12:46:52.73Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-global-rare-diseases-presents-long-term-results-from-phase-3-balance-and-bright-studies-in-fabry-disease-at-the-19th-annual-worldsymposium-research-meeting.html2026-09-18T12:46:52.778Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-global-rare-diseases-and-protalix-biotherapeutics-receive-positive-chmp-opinion-for-pegunigalsidase-alfa-for-treatment-of-fabry-disease.html2026-09-18T12:46:52.989Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-and-affibody-collaborate-to-develop-and-commercialize-innovative-treatments-for-respiratory-diseases.html2026-09-18T12:46:53.033Zhttps://www.chiesi.com/en/media-hub/press-release/restore-to-impact-the-next-healthcare-landmark-for-innovation-and-future-oriented-competencies.html2026-09-18T12:46:53.08Zhttps://www.chiesi.com/en/media-hub/press-release/2022-for-chiesi-the-grouprs-international-growth-continues.html2026-09-18T12:46:53.123Zhttps://www.chiesi.com/en/media-hub/press-release/acquisition-amryt-pharma.html2026-09-18T12:46:53.165Zhttps://www.chiesi.com/en/media-hub/press-release/authorization-pegunigalsidase-alfa-fabry-disease.html2026-09-18T12:46:53.214Zhttps://www.chiesi.com/en/media-hub/press-release/fda-approval-prx-102-fabry-disease.html2026-09-18T12:46:53.259Zhttps://www.chiesi.com/en/media-hub/press-release/movie-rare-land-alpha-mannosidosis.html2026-09-18T12:46:53.302Zhttps://www.chiesi.com/en/media-hub/press-release/alessandro-chiesi-chair-maria-paola-chiesi-vice-chair.html2026-09-18T12:46:53.345Zhttps://www.chiesi.com/en/media-hub/press-release/sustainability-report-2022.html2026-09-18T12:46:53.388Zhttps://www.chiesi.com/en/media-hub/press-release/mid-year-financial-results-2023.html2026-09-18T12:46:53.439Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-global-rare-diseases-ssiem-symposium-2023.html2026-09-18T12:46:53.482Zhttps://www.chiesi.com/en/media-hub/press-release/climate-change-respiratory-patients.html2026-09-18T12:46:53.527Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-foundation-nest-partners-meeting.html2026-09-18T12:46:53.569Zhttps://www.chiesi.com/en/media-hub/press-release/partnership-day-2023.html2026-09-18T12:46:53.61Zhttps://www.chiesi.com/en/media-hub/press-release/report-burden-care-rare-diseases.html2026-09-18T12:46:53.654Zhttps://www.chiesi.com/en/media-hub/press-release/agreement-haisco-pharmaceutical-reversible-dipeptidyl-peptidase-1-inhibitor-bronchiectasis.html2026-09-18T12:46:53.696Zhttps://www.chiesi.com/en/media-hub/press-release/restore-to-impact-award-ceremony.html2026-09-18T12:46:53.739Zhttps://www.chiesi.com/en/media-hub/press-release/impact-climate-change-respiratory-conditions.html2026-09-18T12:46:53.782Zhttps://www.chiesi.com/en/media-hub/press-release/oscar-bilancio-benefit-corporation-category.html2026-09-18T12:46:53.825Zhttps://www.chiesi.com/en/media-hub/press-release/global-rare-diseases-approval-filsuvezr.html2026-09-18T12:46:53.873Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-oak-hill-bio-ohb-607-neonatal-therapy.html2026-09-18T12:46:53.916Zhttps://www.chiesi.com/en/media-hub/press-release/past-present-future.html2026-09-18T12:46:53.961Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-announces-passing-honorary-president-dr-paolo-chiesi.html2026-09-18T12:46:54.002Zhttps://www.chiesi.com/en/media-hub/press-release/new-supplementary-labor-agreement-italy.html2026-09-18T12:46:54.054Zhttps://www.chiesi.com/en/media-hub/press-release/carbon-minimal-inhalers-milestone.html2026-09-18T12:46:54.098Zhttps://www.chiesi.com/en/media-hub/press-release/2023-revenue.html2026-09-18T12:46:54.14Zhttps://www.chiesi.com/en/media-hub/press-release/gossamer-bio-collaboration-pulmonary-arterial-hypertension.html2026-09-18T12:46:54.187Zhttps://www.chiesi.com/en/media-hub/press-release/alliance-karolinska-institutet-health-challenges.html2026-09-18T12:46:54.238Zhttps://www.chiesi.com/en/media-hub/press-release/oak-hill-bio-and-chiesi-group-announce-first-patient-enrolled-in-the-resumed-phase-2b-clinical-study-evaluating-ohb-607-for-the-prevention-of-bronchopulmonary-dysplasia-the-most-common-cause-of-chronic-lung-disease-in-premature-infants.html2026-09-18T12:46:54.282Zhttps://www.chiesi.com/en/media-hub/press-release/sustainability-strategy-create-shared-value-insights-2023-sustainability-report.html2026-09-18T12:46:54.326Zhttps://www.chiesi.com/en/media-hub/press-release/unveils-innovations-respiratory-patient-decentralization-carbon-minimal-inhaler.html2026-09-18T12:46:54.369Zhttps://www.chiesi.com/en/media-hub/press-release/biotech-center-parma-opening.html2026-09-18T12:46:54.421Zhttps://www.chiesi.com/en/media-hub/press-release/world-best-workplaces-2024.html2026-09-18T12:46:54.472Zhttps://www.chiesi.com/en/media-hub/press-release/new-independent-non-executive-directors-board.html2026-09-18T12:46:54.529Zhttps://www.chiesi.com/en/media-hub/press-release/nerviano-manufacturing-site.html2026-09-18T12:46:54.577Zhttps://www.chiesi.com/en/media-hub/press-release/2024-growth-innovation-sustainability.html2026-09-18T12:46:54.628Zhttps://www.chiesi.com/en/media-hub/press-release/sustainability-report-2024-chiesi-purpose-first.html2026-09-18T12:46:54.678Zhttps://www.chiesi.com/en/media-hub/press-release/elgn-2112-phase-3-study-preterm-infants.html2026-09-18T12:46:54.729Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-serna-bio-strategic-collaboration-rna-small-molecules-respiratory-diseases.html2026-09-18T12:46:54.778Zhttps://www.chiesi.com/en/media-hub/press-release/filsuvez-swissmedic-approval-epidermolysis-bullosa.html2026-09-18T12:46:54.827Zhttps://www.chiesi.com/en/media-hub/press-release/sustainable-growth-2025-financial-results-shared-value.html2026-09-18T12:46:54.878Zhttps://www.chiesi.com/en/media-hub/press-release/pmdi-carbon-minimal-clinical-development-regulatory-submissions.html2026-09-18T12:46:54.929Zhttps://www.chiesi.com/en/media-hub/press-release/rare-disease-gene-editing-partnership-chiesi-arbor.html2026-09-18T12:46:54.979Zhttps://www.chiesi.com/en/media-hub/press-release/industrial-site-expansion-la-chaussee-saint-victor-sustainable-respiratory-solutions.html2026-09-18T12:46:55.031Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-aliada-abbvie-license-agreement-lysosomal-storage-disorders.html2026-09-18T12:46:55.079Zhttps://www.chiesi.com/en/media-hub/press-release/carbon-minimal-inhaler-cmi-therapeutic-equivalence-bts-winter-meeting.html2026-09-18T12:46:55.13Zhttps://www.chiesi.com/en/media-hub/press-release/elfabrio-chmp-positive-opinion-four-week-dosing-eu.html2026-09-18T12:46:55.186Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-bespak-carbon-minimal-inhaler-production-uk.html2026-09-18T12:46:55.237Zhttps://www.chiesi.com/en/media-hub/press-release/elfabrio-european-commission-approval-four-week-dosing.html2026-09-18T12:46:55.288Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-global-rare-diseases-positive-chmp-opinion-lojuxta.html2026-09-18T12:46:55.341Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-salesforce-agentforce-life-sciences-customer-engagement.html2026-09-18T12:46:55.391Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-reports-strong-fy2025-financial-sustainability-results.html2026-09-18T12:46:55.444Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-to-acquire-kalvista-pharmaceuticals-expanding-its-global-rare-disease-portfolio.html2026-09-18T12:46:55.497Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-announces-new-chair-and-vice-chair.html2026-09-18T12:46:55.548Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-completes-acquisition-of-kalvista-pharmaceuticals.html2026-09-18T12:46:55.706Zhttps://www.chiesi.com/en/media-hub/press-release/persistent-asthma-the-innovative-inhaler-available-in-italy.html2026-09-25T14:32:22.581Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-global-rare-diseases-announces-european-commission-approval-of-lojuxta-lomitapide.html2026-09-28T08:16:53.287Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-receives-european-marketing-authorisation-for-single-inhaler-triple-therapy-delivered-via-nexthaler-for-maintenance-treatment-of-Asthma.html2026-09-28T08:17:17.993Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-advances-carbon-minimal-inhaler-journey-as-european-submissions-for-single-inhaler-triple-therapy-and-ics-laba-combination-next-generation-propellant-pmdis-are-validated.html2026-10-02T14:07:55.085Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-appoints-david-khougazian-as-group-chief-executive-officer-to-lead-the-next-phase-of-innovation-driven-growth-1.html2026-09-28T08:19:07.175Zhttps://www.chiesi.com/en/media-hub/press-release/chiesi-group-delivers-solid-h1-2026-performance-combining-growth-continued-investment-positive-economic-impact.html2026-10-02T15:14:29.582Zhttps://www.chiesi.com/en/media-hub/news/double-digit-growth-and-internal-expansion-for-the-chiesi-group.html2026-09-18T12:46:44.476Zhttps://www.chiesi.com/en/media-hub/news/copd-indication-for-foster-pmdi.html2026-09-18T12:46:44.519Zhttps://www.chiesi.com/en/media-hub/news/chiesi-is-top-employer-again.html2026-09-18T12:46:44.559Zhttps://www.chiesi.com/en/media-hub/news/special-mention-to-holoclar-at-the-italian-galeno-award.html2026-09-18T12:46:44.6Zhttps://www.chiesi.com/en/media-hub/news/alberto-paolo-and-andrea-chiesi-winners-of-the-entrepreneur-of-the-year-2015-award.html2026-09-18T12:46:44.641Zhttps://www.chiesi.com/en/media-hub/news/chiesi-certified-top-employer-also-for-2017.html2026-09-18T12:46:44.681Zhttps://www.chiesi.com/en/media-hub/news/chiesi-farmaceutici-completes-the-acquisition-of-european-marketing-rights.html2026-09-18T12:46:44.724Zhttps://www.chiesi.com/en/media-hub/news/chiesi-enters-into-an-exclusive-ex-us-partnership-with-protalix-biotherapeutics-for-the-development-and-commercialization-of-prx-102-pegunigalsidase-alfa-for-the-treatment-of-fabry-disease.html2026-09-18T12:46:44.766Zhttps://www.chiesi.com/en/media-hub/news/bio-europe-2018.html2026-09-18T12:46:44.806Zhttps://www.chiesi.com/en/media-hub/news/chiesi-digital-transformation-digital-safari-workshop-with-david-orban.html2026-09-18T12:46:44.848Zhttps://www.chiesi.com/en/media-hub/news/global-corporate-development-opening-of-new-offices-in-boston.html2026-09-18T12:46:44.888Zhttps://www.chiesi.com/en/media-hub/news/chiesi-supports-the-third-day-exhibition-dedicated-to-the-relationship-between-man-and-nature.html2026-09-18T12:46:44.931Zhttps://www.chiesi.com/en/media-hub/news/chiesi-signs-a-deal-with-startup-health-first-investment-in-the-digital-area.html2026-09-18T12:46:44.971Zhttps://www.chiesi.com/en/media-hub/news/startup-health-raises-31-million-dollars-from-the-chiesi-group-and-a-prominent-group-of-other-large-pharmaceuticals-companies-and-healthcare-organizations.html2026-09-18T12:46:45.015Zhttps://www.chiesi.com/en/media-hub/news/chiesi-enters-in-an-exclusive-global-license-agreement-with-tiumbio-to-develop-innovative-molecules-for-respiratory-diseases.html2026-09-18T12:46:45.064Zhttps://www.chiesi.com/en/media-hub/news/chiesi-imprese-per-innovazione-award-industry-40-and-sustainability-special-mentions.html2026-09-18T12:46:45.106Zhttps://www.chiesi.com/en/media-hub/news/chiesi-group-enters-into-license-agreement-with-santhera-for-a-treatment-for-lhon.html2026-09-18T12:46:45.148Zhttps://www.chiesi.com/en/media-hub/news/chiesi-group-signs-an-option-agreement-with-inhibrx-for-development-and-commercialization-of-inbrx-101-28aat-fc-29.html2026-09-18T12:46:45.189Zhttps://www.chiesi.com/en/media-hub/news/chiesi-group-announces-closing-of-licensing-transaction-with-santhera-for-an-orphan-drug-in-lhon.html2026-09-18T12:46:45.232Zhttps://www.chiesi.com/en/media-hub/news/chiesi-group-and-apotex-inc-finalize-agreement-for-acquisition-of-ferriprox-deferiprone.html2026-09-18T12:46:45.273Zhttps://www.chiesi.com/en/media-hub/news/chiesi-group-announces-establishment-of-new-global-rare-diseases-division.html2026-09-18T12:46:45.315Zhttps://www.chiesi.com/en/media-hub/news/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-submission-of-biologics-license-application-to-us-food-and-drug-administration-for-pegunigalsidase-alfa-for-the-treatment-of-fabry-disease.html2026-09-18T12:46:45.359Zhttps://www.chiesi.com/en/media-hub/news/happinesswellbeing-maria-paola-chiesi-at-the-vatican-workshop.html2026-09-18T12:46:45.399Zhttps://www.chiesi.com/en/media-hub/news/chiesi-group-and-holostem-terapie-avanzate-announce-transfer-of-holoclar-from-the-chiesi-group-to-holostem.html2026-09-18T12:46:45.442Zhttps://www.chiesi.com/en/media-hub/news/the-b-change-the-instant-book-by-pharmastar-is-online.html2026-09-18T12:46:45.481Zhttps://www.chiesi.com/en/media-hub/news/chiesi-joins-the-movement-of-italian-b-corp-companies-unlock-the-change.html2026-09-18T12:46:45.522Zhttps://www.chiesi.com/en/media-hub/news/italy-for-climate-chiesi-at-the-forefront-for-the-future-of-italy.html2026-09-18T12:46:45.562Zhttps://www.chiesi.com/en/media-hub/news/regeneration-20-3-2c-the-first-global-meeting-to-launch-the-program-is-in-parma-on-october-15-and-16.html2026-09-18T12:46:45.602Zhttps://www.chiesi.com/en/media-hub/news/chiesi-usa-inc-announces-fda-approval-of-bronchitol-mannitol-inhalation-powder.html2026-09-18T12:46:45.646Zhttps://www.chiesi.com/en/media-hub/news/world-prematurity-day-chiesi-is-at-the-forefront-for-preterm-babies.html2026-09-18T12:46:45.692Zhttps://www.chiesi.com/en/media-hub/news/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-extension-of-pdufa-date-for-pegunigalsidase-alfa-for-the-proposed-treatment-of-fabry-disease.html2026-09-18T12:46:45.736Zhttps://www.chiesi.com/en/media-hub/news/the-chiesi-group-is-on-twitter-21.html2026-09-18T12:46:45.776Zhttps://www.chiesi.com/en/media-hub/news/new-record-for-the-chiesi-group-2c-which-is-confirmed-top-italian-pharmaceutical-company-for-number-of-patents-filed.html2026-09-18T12:46:45.819Zhttps://www.chiesi.com/en/media-hub/news/dai-policy-a-further-demonstration-of-chiesi-5c-s-commitment.html2026-09-18T12:46:45.861Zhttps://www.chiesi.com/en/media-hub/news/chiesi-group-is-among-sustainability-leaders-2021-companies-in-italy.html2026-09-18T12:46:45.902Zhttps://www.chiesi.com/en/media-hub/news/werre-all-aware-of-the-climate-crisis-2c-but-werre-not-talking-about-its-impact-on-respiratory-health.html2026-09-18T12:46:45.943Zhttps://www.chiesi.com/en/media-hub/news/we-act-day-2021-this-yearrs-edition-of-chiesirs-event-for-a-sustainable-future.html2026-09-18T12:46:45.984Zhttps://www.chiesi.com/en/media-hub/news/chiesi-supports-the-sao-paulo-declaration-on-planetary-health.html2026-09-18T12:46:46.026Zhttps://www.chiesi.com/en/media-hub/news/the-president-alberto-chiesi-guest-at-the-farmindustria-roadshow.html2026-09-18T12:46:46.065Zhttps://www.chiesi.com/en/media-hub/news/head-of-chiesi-global-rare-diseases-recognized-at-rare-champions-of-hope-awards-2021.html2026-09-18T12:46:46.105Zhttps://www.chiesi.com/en/media-hub/news/chiesi-wins-the-diversity-leaders-award-for-the-third-consecutive-year.html2026-09-18T12:46:46.148Zhttps://www.chiesi.com/en/media-hub/news/lhelping-the-world-to-breather-chiesi-group-among-the-protagonist-of-the-ats-docuseries.html2026-09-18T12:46:46.188Zhttps://www.chiesi.com/en/media-hub/news/partners-and-suppliers-protagonists-of-chiesi-vendor-day-2021.html2026-09-18T12:46:46.231Zhttps://www.chiesi.com/en/media-hub/news/world-prematurity-day-chiesirs-commitment-for-the-premature-babies.html2026-09-18T12:46:46.279Zhttps://www.chiesi.com/en/media-hub/news/why-biotech-world-needs-new-plants.html2026-09-18T12:46:46.321Zhttps://www.chiesi.com/en/media-hub/news/the-way-towards-a-sustainable-and-resilient-healthcare.html2026-09-18T12:46:46.363Zhttps://www.chiesi.com/en/media-hub/news/a-musical-manifesto-to-rewrite-the-future.html2026-09-18T12:46:46.404Zhttps://www.chiesi.com/en/media-hub/news/innovating-for-the-health-of-the-planet-and-people-starting-from-the-little-things.html2026-09-18T12:46:46.449Zhttps://www.chiesi.com/en/media-hub/news/dear-colleagues-2c-it-5c-s-showtime-21.html2026-09-18T12:46:46.489Zhttps://www.chiesi.com/en/media-hub/news/the-art-of-healing.html2026-09-18T12:46:46.53Zhttps://www.chiesi.com/en/media-hub/news/co2alizione-italia-not-just-a-declaration-of-intent.html2026-09-18T12:46:46.571Zhttps://www.chiesi.com/en/media-hub/news/new-record-for-chiesi-group-in-2021-its-confirmed-top-italian-pharmaceutical-company-for-number-of-patents-filed.html2026-09-18T12:46:46.612Zhttps://www.chiesi.com/en/media-hub/news/chiesi-group-joins-biden-administration-pledge-to-decarbonize-healthcare-sector.html2026-09-18T12:46:46.653Zhttps://www.chiesi.com/en/media-hub/news/a-new-eu-proposal-to-protect-people-and-planet-by-reducing-f-gases.html2026-09-18T12:46:46.693Zhttps://www.chiesi.com/en/media-hub/news/giacomo-chiesi-awarded-by-pharmavoice100.html2026-09-18T12:46:46.733Zhttps://www.chiesi.com/en/media-hub/news/fostering-innovation-for-rare-diseases-in-europe-chiesi-supports-the-rdr-challenges-call.html2026-09-18T12:46:46.774Zhttps://www.chiesi.com/en/media-hub/news/chiesi-recognized-by-biden-administration-for-its-support-and-commitment-to-greater-resilience-in-the-fight-against-climate-change.html2026-09-18T12:46:46.815Zhttps://www.chiesi.com/en/media-hub/news/vendor-day-the-role-of-chiesi-groups-value-chain-in-shaping-the-future.html2026-09-18T12:46:46.855Zhttps://www.chiesi.com/en/media-hub/news/energize-programme-a-shared-commitment-to-accelerate-the-adoption-of-renewable-energy-in-the-pharmaceutical-sector.html2026-09-18T12:46:46.909Zhttps://www.chiesi.com/en/media-hub/news/from-cells-to-packaging.html2026-09-18T12:46:46.95Zhttps://www.chiesi.com/en/media-hub/news/chiesirs-new-interim-ceo.html2026-09-18T12:46:46.989Zhttps://www.chiesi.com/en/media-hub/news/discovering-esg-criterias-environmental-social-and-governance-the-chiesi-groups-committment.html2026-09-18T12:46:47.034Zhttps://www.chiesi.com/en/media-hub/news/the-alphabet-of-sustainability.html2026-09-18T12:46:47.074Zhttps://www.chiesi.com/en/media-hub/news/the-chiesi-group-and-gender-equality-a-concrete-achievement-now-certified-by-bureau-veritas.html2026-09-18T12:46:47.118Zhttps://www.chiesi.com/en/media-hub/news/chiesi-group-stands-in-solidarity-with-the-people-of-turkiye-and-syria.html2026-09-18T12:46:47.158Zhttps://www.chiesi.com/en/media-hub/news/rare-disease-day.html2026-09-18T12:46:47.198Zhttps://www.chiesi.com/en/media-hub/news/what-does-it-mean-to-be-a-b-corp-chiesi-5c-s-choice-for-a-sustainable-future.html2026-09-18T12:46:47.24Zhttps://www.chiesi.com/en/media-hub/news/in-2022-chiesi-group-has-been-confirmed-as-the-1st-italian-pharmaceutical-company-for-the-number-of-patents-filed.html2026-09-18T12:46:47.28Zhttps://www.chiesi.com/en/media-hub/news/european-parliament-vote-on-the-revision-of-the-eus-legislative-framework-on-f-gas-climate-targets-need-innovative-solutions.html2026-09-18T12:46:47.321Zhttps://www.chiesi.com/en/media-hub/news/world-health-day.html2026-09-18T12:46:47.36Zhttps://www.chiesi.com/en/media-hub/news/a-behavioral-therapy-app-to-close-the-access-gap-in-copd-treatment.html2026-09-18T12:46:47.401Zhttps://www.chiesi.com/en/media-hub/news/leed-certification-sustainability.html2026-09-18T12:46:47.442Zhttps://www.chiesi.com/en/media-hub/news/chiesis-2022-sustainability-report-purpose-first.html2026-09-18T12:46:47.482Zhttps://www.chiesi.com/en/media-hub/news/human-rights-policy.html2026-09-18T12:46:47.523Zhttps://www.chiesi.com/en/media-hub/news/statkraft-energy-ppa.html2026-09-18T12:46:47.562Zhttps://www.chiesi.com/en/media-hub/news/open-day-2023.html2026-09-18T12:46:47.601Zhttps://www.chiesi.com/en/media-hub/news/chiesi-partnershipday-2023.html2026-09-18T12:46:47.647Zhttps://www.chiesi.com/en/media-hub/news/great-place-to-work-recertification.html2026-09-18T12:46:47.688Zhttps://www.chiesi.com/en/media-hub/news/commitment-against-workplace-harassment-violence.html2026-09-18T12:46:47.73Zhttps://www.chiesi.com/en/media-hub/news/empowering-women-gender-equality.html2026-09-18T12:46:47.77Zhttps://www.chiesi.com/en/media-hub/news/chiesi-investment-women-fair-pay-certification.html2026-09-18T12:46:47.811Zhttps://www.chiesi.com/en/media-hub/news/medal-ecovadis.html2026-09-18T12:46:47.851Zhttps://www.chiesi.com/en/media-hub/news/iso-37001-2016-certification-anti-bribery-management-system.html2026-09-18T12:46:47.897Zhttps://www.chiesi.com/en/media-hub/news/empowering-diversity-a-inclusion-chiesi-affinity-networks.html2026-09-18T12:46:47.945Zhttps://www.chiesi.com/en/media-hub/news/chiesi-to-present-data-at-the-american-thoracic-society-conference.html2026-09-18T12:46:47.985Zhttps://www.chiesi.com/en/media-hub/news/code-interdependence-workshop-great-opportunity-collaboration.html2026-09-18T12:46:48.035Zhttps://www.chiesi.com/en/media-hub/news/science-emissions-reduction-validated-by-the-sbti.html2026-09-18T12:46:48.084Zhttps://www.chiesi.com/en/media-hub/news/chiesi-group-reaffirms-ecovadis-platinum-medal.html2026-09-18T12:46:48.13Zhttps://www.chiesi.com/en/media-hub/news/sustainability-inclusivity-updated-code-interdependence.html2026-09-18T12:46:48.177Zhttps://www.chiesi.com/en/media-hub/news/memory-dr-paolo-chiesi.html2026-09-18T12:46:48.224Zhttps://www.chiesi.com/en/media-hub/news/leed-certification-sustainable-workspaces-people-planet.html2026-09-18T12:46:48.27Zhttps://www.chiesi.com/en/media-hub/news/iso-37001-certification-extension-to-affiliates.html2026-09-18T12:46:48.317Zhttps://www.chiesi.com/en/media-hub/news/tanimilast-phase-3-pilaster-study-copd-results.html2026-09-18T12:46:48.364Zhttps://www.chiesi.com/en/media-hub/news/tanimilast-program-discontinuation.html2026-09-18T12:46:48.416Zhttps://www.chiesi.com/en/media-hub/news/mhra-submission-carbon-minimal-inhaler-chiesi.html2026-09-18T12:46:48.464Zhttps://www.chiesi.com/en/media-hub/news/seralutinib-phase-3-prosera-topline-results-pah.html2026-09-18T12:46:48.511Zhttps://www.chiesi.com/en/media-hub/news/us-fda-approves-trimbow-for-maintenance-treatment-of-asthma-in-adults.html2026-09-18T12:46:48.559Zhttps://www.chiesi.com/en/media-hub/news/chiesi-and-oak-hill-bio-holdings-complete-patient-enrollment-in-the-phase-2b-footprints-study.html2026-09-28T07:44:00.128Zhttps://www.chiesi.com/en/media-hub/news/chiesi-marks-significant-step-in-net-zero-journey-with-mhra-approval-of-first-pressurized-metered-dose-inhalers-containing-next-generation-low-gwp-propellant.html2026-09-28T08:02:43.016Zhttps://www.chiesi.com/en/media-hub/news/chiesi-announcesa-partnership-with-abdi-ibrahim-in-turkiye.html2026-09-28T09:52:12.295Zhttps://www.chiesi.com/en/media-hub/news/chiesi-group-chair-signs-open-letter-calling-for-stronger-support-for-pharmaceutical-innovation-in-europe.html2026-09-28T09:53:03.606Zhttps://www.chiesi.com/en/media-hub/news/chiesi-returns-seralutinib-rights-to-gossamer-bio-companies-terminate-collaboration-and-license-agreement.html2026-09-28T09:53:48.958Zhttps://www.chiesi.com/en/partner-with-us.html2026-10-06T11:19:05.627Zhttps://www.chiesi.com/en/purpose.html2026-09-30T13:48:56.469Zhttps://www.chiesi.com/en/purpose/environment.html2026-10-06T10:27:45.15Zhttps://www.chiesi.com/en/purpose/patients.html2026-10-06T10:27:03.972Zhttps://www.chiesi.com/en/purpose/people.html2026-10-06T10:28:35.069Zhttps://www.chiesi.com/en/purpose/prosperity.html2026-10-06T10:30:13.132Zhttps://www.chiesi.com/en/social-media-terms-of-use.html2026-09-18T12:47:05.472Zhttps://www.chiesi.com/en/sitemap.html2026-09-18T12:47:05.561Zhttps://www.chiesi.com/en/website-terms-of-use.html2026-10-02T16:03:57.723Zhttps://www.chiesi.com/en/certification-notice.html2026-09-18T12:47:12.662Zhttps://www.chiesi.com/en/pharmacovigilance.html2026-09-27T19:26:57.943Zhttps://www.chiesi.com/en/archive.html2026-09-29T15:33:04.221Zhttps://www.chiesi.com/en/privacy.html2026-10-02T10:20:44.014Zhttps://www.chiesi.com/en/cookies.html2026-09-23T13:23:12.463Zhttps://www.chiesi.com/en/accessibility.html2026-09-24T09:43:39.288Z